Volume 5, Issue 3 And 4 (7-2017)                   JoMMID 2017, 5(3 And 4): 56-61 | Back to browse issues page

‎ 10.29252/JoMMID.5.3.4.56

XML Print

The Role of the Gray Wolf in Rabies Transmission in Iran and Preliminary Assessment of an Oral Rabies Vaccine in this Animal
Alireza Gholami , Siamak Massoudi , Majid Kharazian Moghaddam , Mahmoud Ghazi Marashi , Mahyar Marashi , Rouzbeh Bashar , Ahmad Fayaz , Maryam Fazeli , Firouzeh Farahtaj , Nader Howaizi , Mohammad Reza Shirzadi
National Reference Center for Rabies, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (5691 Views)
Introduction: In Iran, 95% of animal bites are attributed to domestic dogs and cats, while one-third of rabies victims are from wildlife. The wolf is one of the primary vectors of wildlife in the country. This study was aimed to assess the impact of wildlife on rabies transmission and to evaluate the efficacy of an oral rabies vaccine (ORV) in the gray wolf (Canis lupus pallipes). Methods: We studied the incidence of wolf attacks by analyzing a 10-year period of data (2000 to 2009) available in the Ministry of Health and Medical Education, the Veterinary Organization and Pasteur Institute of Iran. In the next step, five captive gray wolves were fed by Raboral V-RG® vaccine baits (Merial®, part of Boehringer Ingelheim, Germany) and monitored for rabies neutralizing antibodies over 20 months by rapid fluorescent focus inhibition test (RFFIT). Results: Our analysis showed that 55% of animal bites occurred in rural areas and the remaining in urban areas. The most rabid wolves were from Fars province in southern Iran. The vaccine baits were palatable for the hungry wolves. Seroconversion with antibodies titers ≥0.5 IU/ml occurred after 12 weeks and maintained for 78 weeks indicating potential protection against rabies after receiving a single ORV bait. Conclusion: Our results suggested that a single dose of vaccination with V-RG®, though initially designed for foxes and raccoons, can protect the gray wolf against rabies as well.
Keywords: Oral rabies vaccination (ORV), Rabies, anti-rabies antibodies, wolf
Full-Text [PDF 612 kb]   (2079 Downloads)    
Type of Study: Original article | Subject: Infectious diseases and public health
Received: 2018/02/20 | Accepted: 2018/02/24 | Published: 2018/04/23
References
1. 1. Sudarshan M, Madhusudana S, Mahendra B, Rao N, Narayana DA, Rahman SA, et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis. 2007; 11 (1): 29-35. [DOI:10.1016/j.ijid.2005.10.007] [PMID]
2. 2. Woldehiwet Z. Rabies: recent developments. Res Vet Sci. 2002; 73 (1):17-25. [DOI:10.1016/S0034-5288(02)00046-2]
3. 3. Rupprecht C, Hanlon C, Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev Biol. 2003; 119: 173-84.
4. 4. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002; 2 (6): 327-43. [DOI:10.1016/S1473-3099(02)00287-6]
5. 5. Okell C, Pinchbeck G, Stringer A, Tefera G, Christley R. A community-based participatory study investigating the epidemiology and effects of rabies to livestock owners in rural Ethiopia. Prev Vet Med. 2013; 108 (1): 1-9. [DOI:10.1016/j.prevetmed.2012.07.003] [PMID]
6. 6. Bahonar A, Rashidi H, Simani S, Fayaz A, Haghdoost A, Rezaei-nassab M, et al. Relative frequency of animal rabies and factors affecting it in Kerman province, 1993-2003. J Sch Public Health Inst Public Health Res. 2007; 5 (1): 69-76.
7. 7. Shirzadi M, Pourmozafari J, Shamsipour M. Status of Animal Bite and Rabies Cases in Northeast Provinces of Iran during 2009-2010. J Zoonoses. 2014; 1 (1).
8. 8. Esfandiari B, Youssefi MR, Fayaz A. Serodiagnosis evaluation of rabies and animal bites in North of Iran, 2010. J Gen Mol Virol. 2011; 3 (5): 71-3. [DOI:10.5897/JGMV11.019]
9. 9. Shariati A. Epidemiology of rabies in Khorasan state during 1994-2003. Prev Vet Dis. 2004: 90.
10. 10. Simani S. Rabies situation in Iran. J Veter Faculty. 2003; 58 (3): 275-8.
11. 11. Rezaeinasab M, Rad I, Bahonar A, Rashidi H, Fayaz A, Simani S, et al. The prevalence of rabies and animal bites during 1994 to 2003 in Kerman province, southeast of Iran. Iran J Vet Res. 2007; 8 (4): 343-50.
12. 12. Wilde H, Khawplod P, Khamoltham T, Hemachudha T, Tepsumethanon V, Lumlerdacha B, et al. Rabies control in south and southeast Asia. Vaccine. 2005; 23 (17): 2284-9. [DOI:10.1016/j.vaccine.2005.01.030] [PMID]
13. 13. Rostampour F, Fallahi A. An epidemiologic study of animal bites in Ilam Province, Iran. Arch Iran Med. 2012; 15 (6): 356. [PMID]
14. 14. Eslamifar A, Ramezani A, Razzaghi-Abyaneh M, Fallahian V, Mashayekhi P, Hazrati M, et al. Animal bites in Tehran, Iran. Arch Iran Med. 2008; 11 (2): 200-2. [PMID]
15. 15. Cleaveland S, Kaare M, Knobel D, Laurenson MK. Canine vaccination-providing broader benefits for disease control. Vet Microbiol. 2006; 117 (1): 43-50. [DOI:10.1016/j.vetmic.2006.04.009] [PMID]
16. 16. Thompson R, Kutz SJ, Smith A. Parasite zoonoses and wildlife: emerging issues. Int J Environ Res Public Health. 2009; 6 (2): 678-93. [DOI:10.3390/ijerph6020678] [PMID] [PMCID]
17. 17. Coleman PG, Dye C. Immunization coverage required to prevent outbreaks of dog rabies. Vaccine. 1996; 14 (3): 185-6. [DOI:10.1016/0264-410X(95)00197-9]
18. 18. Brochier B, Blancou J, Thomas I, Languet B, Artois M, Kieny M-P, et al. Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species. J Wildl Dis. 1989; 25 (4): 540-7. [DOI:10.7589/0090-3558-25.4.540] [PMID]
19. 19. Zhugunissov K, Bulatov Ye, Taranov D, Yershebulov Z, Koshemetov Zh, Abduraimov Ye, et al. Protective immune response of oral rabies vaccine in stray dogs, corsacs and steppe wolves after a single immunization. Arch Virol. 2017. [DOI:10.1007/s00705-017-3499-6] [PMID]
20. 20. Cliquet F, Gurbuxani J, Pradhan H, Pattnaik B, Patil S, Regnault A, et al. The safety and efficacy of the oral rabies vaccine SAG2 in Indian stray dogs. Vaccine. 2007; 25 (17): 3409-18. [DOI:10.1016/j.vaccine.2006.12.054] [PMID]
21. 21. Pastoret P-P, Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiol Infect. 1996; 116 (03): 235-40. [DOI:10.1017/S0950268800052535]
22. 22. Pastoret P, Brochier B. Epidemiology and control of fox rabies in Europe. Vaccine. 1999; 17 (13-14): 1750-4. [DOI:10.1016/S0264-410X(98)00446-0]
23. 23. Slate D, Rupprecht CE, Rooney JA, Donovan D, Lein DH, Chipman RB. Status of oral rabies vaccination in wild carnivores in the United States. Virus Res. 2005; 111 (1): 68-76. [DOI:10.1016/j.virusres.2005.03.012] [PMID]
24. 24. Gholami A, Farahtaj F, Fayaz A. Rabies in Iran: Past, Present, and Future. J Med Microbiol Infect Dis. 2014; 2 (1) 1-10.
25. 25. Slate D, Algeo TP, Nelson KM, Chipman RB, Donovan D, Blanton JD, et al. Oral rabies vaccination in North America: opportunities, complexities, and challenges. PLoS Negl Trop Dis. 2009; 3 (12): e549. [DOI:10.1371/journal.pntd.0000549] [PMID] [PMCID]
26. 26. Rosatte RC, Power MJ, Machines CD, Campbell JB. Trap-vaccinate-release and oral vaccination for rabies control in urban skunks, raccoons and foxes. J Wildl Dis. 1992; 28 (4): 562-71. [DOI:10.7589/0090-3558-28.4.562] [PMID]
27. 27. Krämer B, Schildger H, Behrensdorf-Nicol H, Hanschmann K, Duchow K. The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines. Biologicals. 2009; 37 (2): 119-26. [DOI:10.1016/j.biologicals.2009.01.001] [PMID]
28. 28. Feyssaguet M, Dacheux L, Audry L, Compoint A, Morize J, Blanchard I, et al. Multicenter comparative study of a new ELISA, PLATELIA™ RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people. Vaccine. 2007; 25 (12): 2244-51. [DOI:10.1016/j.vaccine.2006.12.012] [PMID]
29. 29. Used NIC. Tactics and Economics of Wildlife Oral Rabies Vaccination, Canada and the United States.
30. 30. WHO Expert Consultation on Rabies: second report, 2013, World Health Organization; IRIS. [Cited 2018 March 3]. Available from: http://apps.who.int/iris/bitstream/10665/85346-/1/9789240690943_eng.pdf.
31. 31. Black JG, Lawson KF. The safety and efficacy of immunizing foxes (Vulpes vulpes) using bait containing attenuated rabies virus vaccine. Can J Comp Med. 1980; 44 (2): 169-76. [PMID] [PMCID]
32. 32. Rupprecht C, Kieny M-P. Development of a vaccinia-rabies glycoprotein recombinant virus vaccine. Rabies: Springer; 1988. 335-64. [DOI:10.1007/978-1-4613-1755-5_15]
33. 33. Meslin F, Fishbein D, Matter H. Rationale and prospects for rabies elimination in developing countries. Curr Top Microbiol Immunol. 1994; 187: 1. [DOI:10.1007/978-3-642-78490-3_1]
34. 34. Warrell MJ. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med Infect Dis. 2012; 10 (1): 1-15. [DOI:10.1016/j.tmaid.2011.12.005] [PMID]
35. 35. Bögel K, Meslin F. Economics of human and canine rabies elimination: guidelines for programme orientation. Bull World Health Organ. 1990;68(3):281. [PMID] [PMCID]
36. 36. Selhorst T, Müller T, Bätza H. Epidemiological analysis of setbacks in oral vaccination in the final stage of fox rabies elimination in densely populated areas in Germany. Dev Biol. 2005; 125: 127-32.
37. 37. Rupprecht CE, Hamir AN, Johnston DH, Koprowski H. Efficacy of a vaccinia-rabies glycoprotein recombinant virus vaccine in raccoons (Procyon lotor). Rev Infect Dis. 1988; 10 (Supplement 4): S803-S9. [DOI:10.1093/clinids/10.Supplement_4.S803] [PMID]
38. 38. Orciari LA, Niezgoda M, Hanlon CA, Shaddock JH, Sanderlin DW, Yager PA, et al. Rapid clearance of SAG-2 rabies virus from dogs after oral vaccination. Vaccine. 2001; 19 (31): 4511-8. [DOI:10.1016/S0264-410X(01)00186-4]
39. 39. Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995; 13 (6): 539-49. [DOI:10.1016/0264-410X(94)00028-L]
40. 40. Yuan Z, Zhang S, Liu Y, Zhang F, Fooks AR, Li Q, et al. A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs. Vaccine. 2008; 26 (10): 1314-21. [DOI:10.1016/j.vaccine.2007.12.050] [PMID]
41. 41. Cliquet F, Barrat J, Guiot A, Cael N, Boutrand S, Maki J, et al. Efficacy and bait acceptance of vaccinia vectored rabies glycoprotein vaccine in captive foxes (Vulpes vulpes), raccoon dogs (Nyctereutes procyonoides) and dogs (Canis familiaris). Vaccine. 2008; 26 (36): 4627-38. [DOI:10.1016/j.vaccine.2008.06.089] [PMID]
42. 42. Vos A, Freuling CM, Hundt B, Kaiser C, Nemitz S, Neubert A, Nolden T, Teifke JP, Te Kamp V, Ulrich R, Finke S, Müller T. Oral vaccination of wildlife against rabies: Differences among host species in vaccine uptake efficiency. Vaccine. 2017 13; 35 (32): 3938-44.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.